RAC 2.20% $1.78 race oncology ltd

General Comments / Chat, page-7701

  1. 945 Posts.
    lightbulb Created with Sketch. 553
    That's True.
    However, we've had a bunch of other patents to cover zantrene and its analogues or derivatives, so this is just another part of the patent forest.
    At least, this isn't a holdup in running preclinicals, or clinical trails.
    Also, the new formulation's patent when granted should cover us till 2043.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.